IGPH — IGEA Pharma NV Share Price
Last trade - 00:00- CH₣0.51m
- CH₣0.90m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -19.32% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | 0 | 0 | 0.07 | 0.1 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
IGEA Pharma NV is a biopharmaceutical company based in the Netherlands. The Company focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The Company develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The Company offers its services in the Netherlands.
Directors
- Francesco Patrocollo NEC (79)
- Vincenzo Moccia CEO (59)
- Rosanna Squitti CSO (53)
- Giovanni Ferrario NID (72)
- Lieven Baten NID (40)
- Barth Green NID (76)
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- December 1st, 2017
- Public Since
- December 20th, 2018
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- SIX Swiss Exchange
- Shares in Issue
- 337,030,142
- Address
- Siriusdreef 17, HOOFDDORP, 2132 WT
- Web
- https://www.igeapharma.nl/
- Phone
- +31 235689494
- Auditors
- Mazars Italia SpA
Latest News for IGPH
Upcoming Events for IGPH
Similar to IGPH
Alcon AG
SIX Swiss Exchange
COLTENE Holding AG
SIX Swiss Exchange
IVF Hartmann Holding AG
SIX Swiss Exchange
Medacta SA
SIX Swiss Exchange
Medartis Holding AG
SIX Swiss Exchange
FAQ
As of Today at 18:11 UTC, shares in IGEA Pharma NV are trading at CH₣0.00. This share price information is delayed by 15 minutes.
Shares in IGEA Pharma NV last closed at CH₣0.00 and the price had moved by -97% over the past 365 days. In terms of relative price strength the IGEA Pharma NV share price has underperformed the FTSE Global All Cap Index by -97.32% over the past year.
The overall consensus recommendation for IGEA Pharma NV is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
IGEA Pharma NV does not currently pay a dividend.
IGEA Pharma NV does not currently pay a dividend.
IGEA Pharma NV does not currently pay a dividend.
To buy shares in IGEA Pharma NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CH₣0.00, shares in IGEA Pharma NV had a market capitalisation of CH₣0.51m.
Here are the trading details for IGEA Pharma NV:
- Country of listing: Switzerland
- Exchange: SWX
- Ticker Symbol: IGPH
Based on an overall assessment of its quality, value and momentum IGEA Pharma NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like IGEA Pharma NV. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -85.4%.
As of the last closing price of CH₣0.00, shares in IGEA Pharma NV were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The IGEA Pharma NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CH₣0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
IGEA Pharma NV's management team is headed by:
- Francesco Patrocollo - NEC
- Vincenzo Moccia - CEO
- Rosanna Squitti - CSO
- Giovanni Ferrario - NID
- Lieven Baten - NID
- Barth Green - NID